Benzinga

FEBRUARY 23, 2023

Redx Pharma and Jounce Therapeutics Inc (NASDAQ: JNCE ) agreed to merge via a proposed all-share transaction. Redx is a clinical-stage biotechnology company focused on discovering and developing small molecule, targeted therapeutics for cancer and fibrotic diseases and cancer-associated fibrosis.

98

98

Benzinga

APRIL 2, 2023

Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Concentra"), which led to Jounce entering into a merger agreement whereby Concentra will acquire Jounce through a cash tender offer for all of Jounce's outstanding shares for $1.85 CAMBRIDGE, Mass.,

40

40

Benzinga

MAY 3, 2023

May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. Concentra Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 CAMBRIDGE, Mass., per share in cash plus a non-tradeable contingent value right (a "CVR") per share.

Marketability 40

Marketability 40

Benzinga

MARCH 27, 2023

March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. per share upfront consideration represents a premium of approximately 75% to Jounce's closing share price immediately prior to the March 14, 2023 public disclosure of Concentra's acquisition proposal. CAMBRIDGE, Mass.,

40

40

Law 360 M&A

MARCH 15, 2023

Jounce Therapeutics Inc. biotechnology company agreed to merge with British rival Redx Pharma PLC to form a $425 million pharmaceutical giant. said on Wednesday that it has received an unsolicited offer from an affiliate of a private equity firm weeks after the U.S.

Private Equity Firm 40

Private Equity Firm Equity 40

Benzinga

FEBRUARY 22, 2023

23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. NASDAQ: JNCE ) today announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction.

Market Capitalization 40

Market Capitalization Marketability 40